Introduction
============

Among the diverse types of human cancers, hematologic or lymphoid malignancies present major therapeutic challenges due to their low survival rates and poor prognosis. New immuno-chemotherapeutic approaches have improved the survival rates overall; however, many patients with hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML), still have poor outcomes due to resistance to chemotherapy, personal therapeutic limits, frequent metastasis, and relapse ([@B8]; [@B16]). Thus, there is a need for new and more sophisticated therapeutic strategies for treatment of hematologic malignancies.

The serine/threonine protein kinase, CK2 (casein kinase 2), modulates multiple signaling pathways involved in hematopoietic cell survival and function, and is therefore a promising drug target ([@B7]; [@B50]; [@B33]). CK2 is constitutively expressed in many cell types. In human cells it typically exists as a tetrameric complex comprising two catalytic alpha subunits (α and α′) and two regulatory (β) subunits ([@B24]). CK2 plays an important role in the regulation and phosphorylation of a broad range of cellular targets ([@B38]; [@B25]; [@B2]; [@B37]; [@B17]; [@B9]). In mice, knockout of the CK2α′ subunit induces developmental defects and knockdown of the CK2α and β subunits results in embryonic lethality ([@B26]; [@B44]). CK2 regulates hematopoiesis-associated signaling cascades as well as multiple biochemical processes involving tumor growth, proliferation, and resistance to cytotoxic agents ([@B33]). In normal cells, CK2 shows ubiquitous localization throughout the nuclear and cytoplasmic compartments, whereas, in cancer cells, CK2 shows greater abundance in the nuclear compartment ([@B10]; [@B23]). This difference in CK2 distribution may be significant with regard to its biochemical function in cancer. CK2 overexpression has been observed in many hematologic cancers, including CLL ([@B29]), multiple myeloma (MM; [@B34]), T-cell acute lymphocytic leukemia (T-ALL; [@B47]), and acute myeloid leukemia (AML; [@B22]; [@B40]). These studies found that CK2α/β mRNA or protein level was increased in cells from several AML patients (approximately 2- to 14-fold more, compared to controls; [@B40]) or from CLL patients (approximately twofold more, compared controls; [@B29]), as well as plasma cells from MM patients (CK2α, 88% and CK2β, 64% of MM patients analyzed; [@B27]). Moreover, CK2 upregulation was correlated with poor prognosis ([@B50]). These studies identify CK2 as a promising therapeutic target for the development of anti-cancer agents for treatment of many hematological cancers.

Downregulation of CK2 and Cancer Cell Survival
==============================================

Overexpression of CK2 has been observed in many cancers, including hematologic cancers such as AML, CLL, T-ALL, and MM ([@B34]; [@B22]; [@B47]; [@B29]). Downregulation of CK2, either by transfection of specific siRNA or plasmid-based expression of kinase-inactive CK2, resulted in reduction of cancer cell viability and induction of apoptosis ([@B11]; [@B52]; [@B48]). Similar to studies addressing non-hematological cancers, RNA interference that targets CK2 was found to induce apoptosis in MM, AML, CLL, and CML ([@B3]; [@B27]; [@B40]; [@B28]). These reports suggest that downregulation of CK2 by RNA interference or CX-4945 treatment enhances cytotoxicity of hematological cancer cells. Consistent with the overexpression-related observations, these downregulation experiments indicate that CK2 may be a valid druggable anti-cancer target for use in treatment of hematological malignancies, not only human solid tumors ([@B42]; [@B29]; [@B21]).

CX-4945
=======

CX-4945 (Silmitasertib) is an orally administered, ATP-competitive inhibitor of both CK2α and CK2α′ catalytic subunits that was first developed by Cylene Pharmaceuticals Inc. ([@B46]; [@B36]). CX-4945 has been investigated in human cancer studies worldwide and is currently in Phase I and II clinical trials (ClinicalTrials.gov Identifier: NCT02128282). The Phase I trial addresses the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin, to determine the maximum tolerated dose (MTD). The subsequent Phase II trial is a randomized study of antitumor activity in cholangiocarcinoma patients, comparing the standard-of-care protocol of gemcitabine plus cisplatin against treatment with CX-4945 in combination with gemcitabine plus cisplatin at the combination MTD determined in the preceding trial.

Mechanism of CX-4945 Inhibition of CK2
======================================

In the molecular model of inhibition, hydrophobic residues in the small and flat ATP binding site of the CK2α subunit can bind ATP or CK2 inhibitors ([@B43]). Downregulation of CK2 kinase activity is expected to be due to the ability of inhibitors to establish polar interactions with the active conformation of CK2α. CX-4945 showed a strong interaction with the ATP binding pocket of CK2, with a *K*~i~ = 0.38 \[0.02 nM with the recombinant human holoenzyme (ααββ; [@B12])\]. This strong binding interaction between CX-4945 and the ATP binding site of CK2 reduces the enzymatic activity and attenuates the downstream, CK2-regulated PI3K/Akt signaling pathway ([@B35]). The mechanistic relationship between CK2 inhibition by CX-4945, the downstream signaling pathways, and cancer cell survival remains to be fully elucidated.

The Effect of CX-4945 in Human Lymphocytic/Lymphoblastic Malignancies
=====================================================================

The efficacy of CX-4945 has been evaluated with a broad range of human hematologic tumors, including CLL, ALL, AML, and lymphomas ([@B39]). These studies demonstrated that CX-4945 exerts strong anti-proliferative activity in CLL biopsy samples. As well as decreasing CLL cell viability (IC~50~ \< 1 μM) when used alone, CX-4945 exerted synergistic effects in combination with several other inhibitors, including GS-1101, ibrutinib, and fludarabine, which regulate B-cell receptor (BCR)-mediated signaling cascades or downstream mediators. CK2 inhibition downregulates signaling mediators that act downstream of BCR, including PI3K and Akt ([@B29], [@B30]; [@B41]; [@B33]).

In primary CLL cells and in the stable CLL cell line MO1043, CX-4945 treatment led to decreased phosphorylation of Akt and PKC, which are downstream targets of PTEN and PI3K ([@B28]). Consistent with the *in vitro* effects observed in CLL cells, CX-4945 also showed anti-tumor activity in a mouse xenograft model. CX-4945 treatment caused delayed tumor growth, and treatment with CX-4945 plus fludarabine showed synergistic effects. This pre-clinical evidence suggests that CX-4945 is likely to show therapeutic activity, and that it represents a good candidate for CLL treatment in combination with other anti-tumor agents.

CK2 overexpression is a hallmark of ALL, and two recent studies investigated the relationship between increased CK2 expression and the cytotoxic activity of CX-4945 in T-cell ALL and B-cell ALL ([@B5]; [@B15]). CK2 was found to induce phosphorylation of the PTEN tumor suppressor and thereby to activate PI3K/Akt/mTOR, which is a signaling axis that is important for cell survival in ALL ([@B49]; [@B51]; [@B20]; [@B6]). CX-4945 treatment resulted in apoptosis of T-cell ALL and B-cell ALL cells ([@B5]; [@B15]).

The Effect of CX-4945 in Human Myeloid Cancers
==============================================

The therapeutic activity of CX-4945 was also evaluated in CML and AML, respectively. CML is characterized by a translocation known as the "Philadelphia chromosome," which results in the fusion protein Bcr-Abl, a protein tyrosine kinase that plays a crucial role in cell proliferation and in maintenance of the CML phenotype ([@B14]). A relationship between Bcr-Abl and CK2 has been previously suggested ([@B18]; [@B32], [@B31]). [@B3] demonstrated that CX-4945 showed anti-tumor activity in imatinib-resistant CML cells. Downregulation of CK2 by CX-4945 or siRNA contributed to the induction of apoptotic cell death. Furthermore, CK2 inhibition affected the sensitivity of AML cells to chemotherapy. Downregulation of CK2 by CX-4945, K27, or siRNA showed synergistic effects on cytotoxicity and apoptosis in acute, primary blasts as well as in AML cell lines ([@B40]). Moreover, CX-4945 increased the chemotherapeutic activity of daunorubicin in AML.

Perspective on Combination Therapy with the CK2 Inhibitor, CX-4945, in Hematological Cancers
============================================================================================

Inhibition of CK2 expression could also be useful in combination therapies for treatment of MM and mantle cell lymphoma (MCL). A recent report demonstrated CK2 overexpression in MM and MCL cells and that downregulation of CK2 with CK2 inhibitors, such as CX-4945 and K27, induced apoptosis ([@B27]). Bortezomib, a proteasome inhibitor, exerted anti-tumor activity in MM and MCL cells by stabilization of IκBα in the NF-κB signaling pathway; however, bortezomib alone proved to be insufficient for effective treatment. When used in conjunction with bortezomib, CX-4945 inhibition of CK2 enhanced the cytotoxic activity and mitochondrial-dependent cell death in MM and MCL cells ([@B27]).

Conclusion
==========

Numerous studies have demonstrated the anti-tumor effects of CX-4945 in leukemias or lymphomas, resulting from inhibition of CK2 expression (Figure [1](#F1){ref-type="fig"}). Based on these results, we propose that CX-4945 has a potential role in novel therapeutic strategies in the future. Additionally, the combination of CX-4945 with various other anti-cancer drugs may be a useful therapeutic strategy for treatment of hematological cancers (Table [1](#T1){ref-type="table"}).

![**Schematic of CK2-mediated signaling pathways inhibited by CX-4945**.](fphar-06-00070-g0001){#F1}

###### 

**Anti-cancer drugs for potential combination therapy with CX-4945 in treatment of human hematological cancers**.

  Disease   Target CK2 subunits   Combined inhibitors   Target                           IC~50~ or *K*~i~   Reference
  --------- --------------------- --------------------- -------------------------------- ------------------ -----------
  CLL       α, α′                 Ibrutinib             BTK (Bruton's tyrosine kinase)   0.5 nM (*K*~i~)    [@B19]
  ALL       α, α′                 Temsirolimus          mTOR                             1.76 μM            [@B45]
  CML       α, β                  Imatinib              Bcr-Abl                          0.6 μM             [@B4]
  AML       α, β                  Daunorubicin          DNA or RNA synthesis             0.02 μM            [@B13]
  MM        α, β                  Bortezomib            20S proteasome                   0.6 nM (*K*~i~)    [@B1]
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